Three-Way Parenthood

Avoiding the transmission of mitochondrial disease takes a trio, but raises a host of logistical issues.

Written byJohn D. Loike, Michio Hirano, and Yehezkel Margalit
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

© JGI/BLEND IMAGES/CORBIS

When first used in humans in the 1970s, in-vitro fertilization (IVF) raised significant ethical, legal, and philosophical concerns. The ability to manipulate human reproduction was viewed in many circles as an attack on the traditional family and an odious attempt to assert human dominion over nature. Terms such as “designer babies” and “playing God” were commonly applied to IVF. Nevertheless, much of the scientific community touted the potential benefits of these technologies, viewing them as the start of a new era of medicine. Indeed, despite those dire predictions four decades ago, IVF is now widely accepted and has enabled infertile couples to conceive more than 5 million healthy babies.

Fourteen years ago, my Columbia University colleagues and I (JL) examined the mitochondrial origins of Dolly, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • John Loike

    John Loike serves as the interim director of bioethics at New York Medical College and as a professor of biology at Touro University. He served previously as the codirector for graduate studies in the Department of Physiology Cellular Biophysics and director of Special Programs in the Center for Bioethics at Columbia University College of Physicians and Surgeons. His biomedical research focuses on how human white blood cells combat infections and cancer. Loike lectures internationally on emerging topics in bioethics, organizes international conferences, and has published more than 150 papers and abstracts in the areas of immunology, cancer, and bioethics. He earned his Ph.D. from the Albert Einstein College of Medicine of Yeshiva University.

    View Full Profile
  • The Scientist Placeholder Image
    This person does not yet have a bio.View Full Profile
  • The Scientist Placeholder Image
    This person does not yet have a bio.View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies